Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Investing Activities (2017 - 2025)

Protagonist Therapeutics' Cash from Investing Activities history spans 9 years, with the latest figure at $48.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 659.48% year-over-year to $48.8 million; the TTM value through Dec 2025 reached -$49.3 million, up 83.53%, while the annual FY2025 figure was -$49.3 million, 83.53% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $48.8 million at Protagonist Therapeutics, up from -$58.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $57.3 million in Q3 2022 and bottomed at -$208.7 million in Q3 2024.
  • The 5-year median for Cash from Investing Activities is -$270500.0 (2022), against an average of -$15.6 million.
  • The largest annual shift saw Cash from Investing Activities plummeted 1657.48% in 2023 before it surged 659.48% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $27.9 million in 2021, then tumbled by 85.88% to $3.9 million in 2022, then tumbled by 1657.48% to -$61.3 million in 2023, then surged by 85.76% to -$8.7 million in 2024, then soared by 659.48% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Cash from Investing Activities are $48.8 million (Q4 2025), -$58.6 million (Q3 2025), and $54.8 million (Q2 2025).